Eric Dietrich
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Eric Dietrich has a total of 6 co-authors. Here are the top co-authors by number of shared publications:
Kyle Davis
Wake Forest Baptist Medical CenterWinston-Salem, NC
2 shared publications- Alpesh Amin
University of California, Irvine, USA
1 shared publication John G Gums
Pharmacy and Medicine, Associate Chair, Department of Pharmacotherapy and Translational Research; Director of Clinical Research, Department of Community Health and Family Medicine, University of Florida
1 shared publicationJohn G. Gums
University of Florida College of Pharmacy, Gainesville
1 shared publicationLogan Netzer
Agile Outcomes ResearchRochester, MN
1 shared publicationVaidyanathan Ganapathy
Sunovion PharmaceuticalsMarlborough, MA
1 shared publication
Latest Publications
- Open Access
- 1 December 2018
- Published by Academy of Managed Care Pharmacy in Journal of Managed Care & Specialty Pharmacy
- Vol. 24 (12) , 1273-1276
Incident-to Billing for Pharmacists
The inclusion of pharmacists on care teams has been shown to improve clinical and economic health outcomes. However, a significant barrier to the widespread incorporation of pharmacists into care teams is the ability to financially support the salary of the pharmacist. A mechanism to improve the ability of pharmacists to generate clinical revenue already exists in the form of incident-to billing, although there remains considerable uncertainty regarding the criteria for incident-to billing and specifically how pharmacists can use this model to capture revenue for clinical services. In this article, we discuss incident-to billing criteria as it pertains to outpatient clinics, common misconceptions related to incident-to billing, and how clinical pharmacists may use this mechanism to generate revenue for the clinical services they provide. DISCLOSURES: This work was not supported by any funding source. The authors have no relevant conflicts of interest to disclose.
- 1 December 2018
- Published by Academy of Managed Care Pharmacy in Journal of Managed Care & Specialty Pharmacy
- Vol. 24 (12) , 1273-1276
Open AccessIncident-to Billing for Pharmacists
The inclusion of pharmacists on care teams has been shown to improve clinical and economic health outcomes. However, a significant barrier to the widespread incorporation of pharmacists into care teams is the ability to financially support the salary of the pharmacist. A mechanism to improve the ability of pharmacists to generate clinical revenue already exists in the form of incident-to billing, although there remains considerable uncertainty regarding the criteria for incident-to billing and specifically how pharmacists can use this model to capture revenue for clinical services. In this article, we discuss incident-to billing criteria as it pertains to outpatient clinics, common misconceptions related to incident-to billing, and how clinical pharmacists may use this mechanism to generate revenue for the clinical services they provide. DISCLOSURES: This work was not supported by any funding source. The authors have no relevant conflicts of interest to disclose.
- 1 September 2018
- Published by Oxford University Press (OUP) in American Journal of Health-System Pharmacy
- Vol. 75 (17) , 1268-1269
Antibiotic use in patients hospitalized with chronic obstructive pulmonary disease
We read with interest the report by Amin and colleagues[1][1] outlining treatment patterns for patients admitted for an acute exacerbation of chronic obstructive pulmonary disease (AECOPD). The authors noted that the majority of patients included in their analysis received appropriate guideline-
- 1 September 2018
- Published by Oxford University Press (OUP) in American Journal of Health-System Pharmacy
- Vol. 75 (17) , 1268-1269
Antibiotic use in patients hospitalized with chronic obstructive pulmonary disease
We read with interest the report by Amin and colleagues[1][1] outlining treatment patterns for patients admitted for an acute exacerbation of chronic obstructive pulmonary disease (AECOPD). The authors noted that the majority of patients included in their analysis received appropriate guideline-
- 23 June 2014
- Published by SAGE Publications in Annals of Pharmacotherapy
- Vol. 48 (9) , 1238-1241
A Statin a Day to Keep the Doctor Away? Comparing Aspirin and Statins for Primary Prevention of Cardiovascular Disease
For the primary prevention of cardiovascular (CV) disease, aspirin reduces the risk for major vascular events by approximately 15% to 20% with an absolute reduction of approximately 0.1%. Major bleeding occurs at an excess of approximately 2 cases per 1000 patient-years with aspirin therapy. For primary prevention, statin therapy has been shown to reduce the risk of CV events by approximately 30% to 40% with an absolute reduction of 1% to 2%. Rhabdomyolysis is rare, with an incidence of 3.4 cases per 100 000 patient-years. Compared with aspirin, statins have a more favorable risk-to-benefit profile for primary prevention.
- 23 June 2014
- Published by SAGE Publications in Annals of Pharmacotherapy
- Vol. 48 (9) , 1238-1241
A Statin a Day to Keep the Doctor Away? Comparing Aspirin and Statins for Primary Prevention of Cardiovascular Disease
For the primary prevention of cardiovascular (CV) disease, aspirin reduces the risk for major vascular events by approximately 15% to 20% with an absolute reduction of approximately 0.1%. Major bleeding occurs at an excess of approximately 2 cases per 1000 patient-years with aspirin therapy. For primary prevention, statin therapy has been shown to reduce the risk of CV events by approximately 30% to 40% with an absolute reduction of 1% to 2%. Rhabdomyolysis is rare, with an incidence of 3.4 cases per 100 000 patient-years. Compared with aspirin, statins have a more favorable risk-to-benefit profile for primary prevention.
- 25 September 2012
- Published by SAGE Publications in Annals of Pharmacotherapy
- Vol. 46 (10) , 1382-1391
Intranasal Fentanyl Spray: A Novel Dosage Form for the Treatment of Breakthrough Cancer Pain
Objective: To review the pharmacology, pharmacokinetics, clinical efficacy, adverse events, dosing, and administration of intranasal fentanyl spray in the treatment of breakthrough cancer pain (BTCP) in adults. Data Sources: Relevant published data were identified using PubMed from inception to April 2012 using the search terms fentanyl nasal spray, intranasal fentanyl, intranasal fentanyl cancer pain, and fentanyl pectin cancer pain. Only articles evaluating the use of intranasal fentanyl spray for cancer pain were selected. Study Selection and Data Extraction: All articles evaluating the pharmacokinetics of intranasal fentanyl or the clinical efficacy of intranasal fentanyl spray for the treatment of BTCP were considered; references of selected articles were manually reviewed to identify further articles. The manufacturer of intranasal fentanyl spray was also contacted to obtain information. Data Synthesis: Intranasal fentanyl spray gained Food and Drug Administration approval for the treatment of BTCP in adults with cancer receiving stable BACKGROUND opioid therapy for chronic pain. In doses ranging from 100 to 800 μg/spray, intranasal fentanyl spray was found to be more effective than placebo and more effective than oral morphine or oral fentanyl formulations in reducing pain for up to 15–45 minutes; onset of analgesia was also improved with intranasal fentanyl spray. The most commonly observed adverse events included nausea, vomiting, vertigo, and dizziness. Conclusions: For the treatment of BTCP, intranasal fentanyl spray offers improved onset of analgesia compared to other oral therapies; this improved onset of analgesia may closely mimic the typical time course of a BTCP episode. Nasal administration may overcome problems such as nausea, vomiting, or xerostomia that may complicate oral administration of analgesics. Potential disadvantages include uncertainty in treating more than 4 BTCP episodes per 24 hours and a higher cost compared to generically available oral opioid analgesics.
- 25 September 2012
- Published by SAGE Publications in Annals of Pharmacotherapy
- Vol. 46 (10) , 1382-1391
Intranasal Fentanyl Spray: A Novel Dosage Form for the Treatment of Breakthrough Cancer Pain
Objective: To review the pharmacology, pharmacokinetics, clinical efficacy, adverse events, dosing, and administration of intranasal fentanyl spray in the treatment of breakthrough cancer pain (BTCP) in adults. Data Sources: Relevant published data were identified using PubMed from inception to April 2012 using the search terms fentanyl nasal spray, intranasal fentanyl, intranasal fentanyl cancer pain, and fentanyl pectin cancer pain. Only articles evaluating the use of intranasal fentanyl spray for cancer pain were selected. Study Selection and Data Extraction: All articles evaluating the pharmacokinetics of intranasal fentanyl or the clinical efficacy of intranasal fentanyl spray for the treatment of BTCP were considered; references of selected articles were manually reviewed to identify further articles. The manufacturer of intranasal fentanyl spray was also contacted to obtain information. Data Synthesis: Intranasal fentanyl spray gained Food and Drug Administration approval for the treatment of BTCP in adults with cancer receiving stable BACKGROUND opioid therapy for chronic pain. In doses ranging from 100 to 800 μg/spray, intranasal fentanyl spray was found to be more effective than placebo and more effective than oral morphine or oral fentanyl formulations in reducing pain for up to 15–45 minutes; onset of analgesia was also improved with intranasal fentanyl spray. The most commonly observed adverse events included nausea, vomiting, vertigo, and dizziness. Conclusions: For the treatment of BTCP, intranasal fentanyl spray offers improved onset of analgesia compared to other oral therapies; this improved onset of analgesia may closely mimic the typical time course of a BTCP episode. Nasal administration may overcome problems such as nausea, vomiting, or xerostomia that may complicate oral administration of analgesics. Potential disadvantages include uncertainty in treating more than 4 BTCP episodes per 24 hours and a higher cost compared to generically available oral opioid analgesics.